Please ensure Javascript is enabled for purposes of website accessibility

Here's Why Genetic Testing Stocks Lost as Much as 26.1% in May

By Maxx Chatsko - Jun 4, 2019 at 1:36PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Wall Street soured on the high-growth industry after first-quarter earnings were reported, but it may have been an overreaction for two stocks.

What happened

The genetic testing industry has been the source of epic growth in recent years, but investors were forced to wade through significant volatility last month following the release of first-quarter earnings results. Shares of Invitae (NVTA -1.10%) led the cliff-diving with a loss of 26.1% in May, followed by a 21.3% decline for Myriad Genetics (MYGN -1.23%) and an 18.8% tumble for Genomic Health (GHDX), according to data from S&P Global Market Intelligence. Invitae is the only member of the trio that posted a positive year-to-date gain.

Wall Street clearly didn't like the business updates from around the industry. However, a closer examination suggests the pessimism is misplaced. Invitae seized an opportunity to rapidly expand revenue at the expense of short-term operating income, while Genomic Health is delivering on metrics that matter most for a well-positioned genetic testing leader. Myriad Genetics, which continues to struggle to grow newer products in an appreciable manner, may have been the only business that deserved a steep haircut.

A researcher in the lab with a disappointed look on his face.

Image source: Getty Images.

So what?

Invitae surprised Wall Street analysts by changing its near-term strategy. Instead of continuing to decrease cash burn and gradually shrink operating losses, CEO Sean George said the business will plow capital into growth opportunities to "put even more distance between Invitae" and its competitors by the end of 2020. That could cause full-year 2019 cash burn to increase 50% year-over-year, although management is confident the investments will deliver more than $220 million in revenue this year and $500 million in revenue in 2020.

That's one heck of a leap in revenue -- and it will depend heavily on the success of the upcoming commercial launch of the company's direct-to-consumer sales channel. Invitae plans to offer clinical-grade genetic tests to individuals without insurance companies or doctors acting as middlemen. Customers will have access to expert interpretation of the results from genetic counselors and a follow-up from a clinician. If the platform succeeds, then it could fundamentally change healthcare and the company's growth trajectory.

While Wall Street analysts sold the idea of wading through more red ink at Invitae, they seem to be misunderstanding the most important drivers for Genomic Health. The business grew Q1 revenue 17% year-over-year and delivered operating income of $11.5 million, almost half of last year's total. Shares fell 11% on the quarterly update.

A rainbow-colored umbrella in a sea of black umbrellas.

Image source: Getty Images.

The miscommunication appears to stem from analysts narrowing in on the average selling prices (ASPs) of genetic tests, while Genomic is focused on expanding market access for its tests. The latter is more important. For instance, selling directly to customers or expanding its presence in European markets with more regulated healthcare markets than the United States both result in lower ASPs, but the increase in testing volume is a better indicator of long-term success.

Wall Street's infatuation with ASPs is probably the result of stumbling growth at Myriad Genetics. Unlike Invitae or Genomic Health, the genetic testing pioneer has a legacy business from the old days of patented genes and low-volume sales of proprietary tests. That segment has struggled to adapt to the high-volume, low-cost reality of today's industry. Making matters worse, the pioneer's efforts to build a competitive portfolio of products using the current industry playbook hasn't enjoyed the same success of its peers.

Therefore, investors might want to tread carefully with Myriad Genetics stock, especially considering a significant chunk of its adjusted earnings growth comes from accounting, rather than improving performance.

Now what

Any industry capable of producing triple-digit revenue increases is bound to encounter turbulence here and there. That said, Wall Street may have overreacted a bit to recent updates from Invitae and Genomic Health, which appear to be on a solid long-term trajectory. Opportunistic investors with a long-term mindset might want to give them a closer look.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Myriad Genetics, Inc. Stock Quote
Myriad Genetics, Inc.
$21.70 (-1.23%) $0.27
Genomic Health, Inc. Stock Quote
Genomic Health, Inc.
Invitae Stock Quote
$3.59 (-1.10%) $0.04

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/23/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.